Predictive Oncology (NASDAQ:POAI) Receives Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Predictive Oncology ( NASDAQ:POAI – Free Report ) in a report issued on Friday, Marketbeat Ratings reports. HC Wainwright also issued estimates for Predictive Oncology’s Q4 2025 earnings at $0.06 EPS, FY2026 earnings at $0.

08 EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.46 EPS.



Predictive Oncology Stock Down 0.7 % POAI stock opened at $0.68 on Friday.

The company has a 50 day moving average of $0.75 and a two-hundred day moving average of $1.05.

The company has a market cap of $4.54 million, a price-to-earnings ratio of -0.22 and a beta of 1.

14. Predictive Oncology has a 12-month low of $0.55 and a 12-month high of $3.

76. Predictive Oncology Company Profile ( Get Free Report ) Recommended Stories Receive News & Ratings for Predictive Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Oncology and related companies with MarketBeat.com's FREE daily email newsletter .

.